Hypertension vaccine CYT006-AngQb achieves strong blood

Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035) Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels

SCHLIEREN, Switzerland and MILAN, Italy | June 17, 2007 |
Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension. On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 μg dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).

SOURCE: Cytos Biotechnology AG

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up